Related references
Note: Only part of the references are listed.Machine Learning and Mechanistic Modeling for Prediction of Metastatic Relapse in Early-Stage Breast Cancer
Chiara Nicolo et al.
JCO CLINICAL CANCER INFORMATICS (2020)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer
Emilia Kozlowska et al.
CANCER RESEARCH (2018)
Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability
Franck Raynaud et al.
PLOS GENETICS (2018)
Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model
Changran Geng et al.
SCIENTIFIC REPORTS (2017)
Tumor evolution: Linear, branching, neutral or punctuated?
Alexander Davis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
Phase i trials in melanoma: A framework to translate preclinical findings to the clinic
Eunjung Kim et al.
EUROPEAN JOURNAL OF CANCER (2016)
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model
Eleni Kolokotroni et al.
PLOS COMPUTATIONAL BIOLOGY (2016)
Dose-Dense Approaches to Ovarian Cancer Treatment
Noriyuki Katsumata
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
The role of the cell-cell interactions in cancer progression
Katarzyna Kaminska et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Tumorigenesis: it takes a village
Doris P. Tabassum et al.
NATURE REVIEWS CANCER (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Laura Astolfi et al.
ONCOLOGY REPORTS (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Robert J. Gillies et al.
NATURE REVIEWS CANCER (2012)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mathematical modeling as a tool for planning anticancer therapy
Andrzej Swierniak et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Turning gray: The natural history of lung cancer over time
Frank C. Detterbeck et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Evolution of resistance during clonal expansion
Y Iwasa et al.
GENETICS (2006)
Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)
A Nicolini et al.
BIOMEDICINE & PHARMACOTHERAPY (2004)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
